联合sFlt-1、CT-pro-ET-1与血压预测重度子痫前期/HELLP综合征:探索性研究
纳入215例孕晚期疑似子痫前期转诊孕妇与94例正常妊娠孕妇,评估血管生成与血管活性生物标志物联合预测1周及2周内进展为重度子痫前期/HELLP综合征的性能。CT-pro-ET-1、sFlt-1与收缩压联合预测1周内进展的AUC为0.94。作者认为该联合预测表现有前景,但属探索性研究,需进一步研究证实。
要点
- CT-pro-ET-1预测1周及2周内进展为重度子痫前期/HELLP综合征的AUC分别为0.82和0.78。
- sFlt-1预测1周及2周内进展的AUC分别为0.81和0.76。
- CT-pro-ET-1、sFlt-1与收缩压联合预测1周内进展的AUC为0.94。
核心结论
- CT-pro-ET-1预测孕晚期进展为子痫前期/HELLP综合征的表现有前景,尤其与sFlt-1和收缩压联合时。
- 本研究为探索性研究,作者认为其发现需在进一步研究中证实。
研究设计与样本
- 纳入215例孕晚期因疑似子痫前期转诊至产科门诊的孕妇(平均孕周35+4周)和94例就诊于助产士门诊的正常妊娠孕妇。
- 将病例分为亚临床子痫前期、原发性高血压、妊娠期高血压、中度子痫前期和重度子痫前期/HELLP综合征。
- 采用免疫分析法检测血样,比较各组临床与生化标志物,主要结局为分析后1周内和2周内进展为重度子痫前期/HELLP综合征。
主要发现
- 在表现为轻至中度子痫前期症状的患者中,预测1周内和2周内进展为重度子痫前期/HELLP综合征表现最佳的单个标志物为CT-pro-ET-1(AUC分别为0.82和0.78)。
- sFlt-1预测1周内和2周内进展的AUC分别为0.81和0.76。
- 收缩压预测1周内和2周内进展的AUC分别为0.80和0.68。
- 中段心房利钠肽前体(MR-proANP)预测1周内和2周内进展的AUC分别为0.79和0.77。
- 表现最佳的标志物联合为CT-pro-ET-1、sFlt-1与收缩压,预测1周内进展为重度子痫前期/HELLP综合征的AUC为0.94,预测2周内进展的AUC为0.83。
关键数值与推荐
- CT-pro-ET-1预测1周内进展的AUC为0.82,预测2周内进展的AUC为0.78。
- sFlt-1预测1周内进展的AUC为0.81,预测2周内进展的AUC为0.76。
- 收缩压预测1周内进展的AUC为0.80,预测2周内进展的AUC为0.68。
- MR-proANP预测1周内进展的AUC为0.79,预测2周内进展的AUC为0.77。
- CT-pro-ET-1、sFlt-1与收缩压联合预测1周内进展的AUC为0.94,预测2周内进展的AUC为0.83。
临床怎么用
- 作者认为CT-pro-ET-1预测孕晚期进展为子痫前期/HELLP综合征的表现有前景,尤其与sFlt-1和收缩压联合时。
- 作者指出本研究为探索性研究,其发现需在进一步研究中证实。
局限性
- 本研究为探索性研究,作者指出其发现需在进一步研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the performance of a combination of angiogenic and vasoactive biomarkers to predict the development of severe pre-eclampsia (PE)/HELLP syndrome in the third trimester. METHODS: Included were 215 women referred in the third trimester to an obstetric outpatient clinic with suspected PE (mean gestational age, 35 + 4 weeks), and 94 with normal pregnancy attending a midwife clinic. Cases were categorized as having subclinical PE, essential hypertension, gestational hypertension, moderate PE, and severe PE/HELLP syndrome. Blood samples were analyzed by immunoassay and groups were compared with respect to potential clinical and biochemical biomarkers, with the primary outcome being development of severe PE/HELLP syndrome within 1 week and within 2 weeks of analysis. The most promising markers were also assessed in combination. RESULTS: In the patients presenting with mild to moderate symptoms of PE, the individual markers which performed best for the prediction of progression to severe PE/HELLP syndrome within 1 week and within 2 weeks of biomarker evaluation were C-terminal pro-endothelin-1 (CT-pro-ET-1) (area under the receiver-operating characteristics curve (AUC), 0.82 and 0.78, respectively), soluble fms-like tyrosine kinase-1 (sFlt-1) (AUC, 0.81 and 0.76), systolic blood pressure (AUC, 0.80 and 0.68) and midregional pro-atrial natriuretic peptide (AUC, 0.79 and 0.77). The combination of biomarkers with the best performance was CT-pro-ET-1, sFlt-1 and systolic blood pressure, achieving an AUC of 0.94 for prediction of development of severe PE/HELLP syndrome within 1 week and an AUC of 0.83 for prediction of their development within 2 weeks of biomarker evaluation. CONCLUSIONS: The performance of CT-pro-ET-1 for prediction of the development of PE/HELLP syndrome in the third trimester was promising, especially in combination with sFlt-1 and systolic blood pressure. This was an exploratory study and our findings should be confirmed in further studies. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Lind Malte A, Uldbjerg N, Wright D, et al. Prediction of severe pre-eclampsia/HELLP syndrome by combination of sFlt-1, CT-pro-ET-1 and blood pressure: exploratory study. Ultrasound Obstet Gynecol. 2018. PMID: 28643875. doi:10.1002/uog.17561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。